Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …

Background: Recently approved for the treatment of schizophrenia, aripiprazole represents
the sixth second-generation antipsychotic (SGA) introduced to the US market. Aripiprazole is …

Background Long-acting injectable risperidone, a second-generation antipsychotic agent,
may improve adherence to treatment and outcomes in schizophrenia, but it has not been …

Background: Medical morbidity and mortality rates remain elevated in schizophrenia
patients compared with the general population, in part due to potentially reversible medical …

The objective of this review is to consider the psychological (largely behavioral) and
biological [neurochemical, medical (including genetic), and pharmacological] theories and …

Background: The metabolic/biotransformation pathways of atypical antipsychotics
(aripiprazole, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and …

Blonanserin was developed as an antipsychotic drug in Japan and approved for the
treatment of schizophrenia. It belongs to a series of 4-phenyl-2-(1-piperazinyl) pyridines and …

This chapter presents an updated review of the history, pharmacology, uses, efficacy, and
side effects of antipsychotic drugs (APDs) on the basis of currently available evidence. It …

Objectives To compare the effects of typical and atypical antipsychotic drugs on sleep
activity and subjective sleep quality. Design Randomised, double-blind, placebo-controlled …